Skip to main content
Back
INVA logo

Innoviva, Inc.

Data quality: 100%
INVA
NASDAQ Healthcare Biotechnology
$21.91
▲ $0.21 (0.97%)
Mkt Cap: 1.41B
Day Range
$21.67 $22.15
52-Week Range
$16.52 $25.15
Volume
831,721
50D / 200D Avg
$21.55 / $20.16
Prev Close
$21.70

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E 5.2 0.4
P/B 1.2 2.9
ROE % 29.1 3.8
Net Margin % 63.8 3.9
Rev Growth 5Y % 2.1 10.0
D/E 0.2 0.2

Key Takeaways

Revenue grew 2.06% annually over 5 years — modest growth
Earnings grew 1059.22% over the past year
ROE of 29.09% indicates high profitability
Net margin of 63.78% shows strong profitability
Debt/Equity of 0.23 — conservative balance sheet
Generating 195.80M in free cash flow

Growth

Revenue Growth (5Y)
2.06%
Revenue (1Y)18.52%
Earnings (1Y)1059.22%
FCF Growth (3Y)17.99%

Quality

Return on Equity
29.09%
ROIC8.52%
Net Margin63.78%
Op. Margin38.52%

Safety

Debt / Equity
0.23
Current Ratio14.64
Interest Coverage9.81

Valuation

P/E Ratio
5.20
P/B Ratio1.20
EV/EBITDA6.89
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 18.52% Revenue Growth (3Y) 17.02%
Earnings Growth (1Y) 1059.22% Earnings Growth (3Y) 22.83%
Revenue Growth (5Y) 2.06% Earnings Growth (5Y) 0.50%
Profitability
Revenue (TTM) 425.13M Net Income (TTM) 271.17M
ROE 29.09% ROA 16.58%
Gross Margin 72.33% Operating Margin 38.52%
Net Margin 63.78% Free Cash Flow (TTM) 195.80M
ROIC 8.52% FCF Growth (3Y) 17.99%
Safety
Debt / Equity 0.23 Current Ratio 14.64
Interest Coverage 9.81 Dividend Yield 0.00%
Valuation
P/E Ratio 5.20 P/B Ratio 1.20
P/S Ratio 3.32 PEG Ratio 0.01
EV/EBITDA 6.89 Dividend Yield 0.00%
Market Cap 1.41B Enterprise Value 1.13B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 425.13M 358.71M 310.46M 331.34M 391.87M
Net Income 271.17M 23.39M 179.72M 213.92M 265.85M
EPS (Diluted) 3.30 0.36 2.20 2.37 2.87
Gross Profit 307.52M 322.11M 267.82M 317.55M 391.87M
Operating Income 163.75M 166.87M 113.89M -36.95M 375.10M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.64B 1.30B 1.24B 1.23B 926.40M
Total Liabilities 462.32M 609.90M 568.55M 665.71M 400.46M
Shareholders' Equity 1.17B 691.16M 674.96M 565.79M 414.74M
Total Debt 269.02M 451.10M 449.08M 544.07M 394.76M
Cash & Equivalents 550.94M 304.96M 193.51M 291.05M 201.53M
Current Assets 727.52M 554.31M 344.22M 443.51M 313.67M
Current Liabilities 49.70M 236.08M 38.13M 134.97M 5.81M

Strategy Scores

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Capital Light Compounder
#46 of 211
53
Custom Contrarian Investing (David Dreman)
#84 of 655
61

Recent Activity

Entered Capital Light Compounder
Mar 24, 2026
Entered Contrarian Investing (David Dreman)
Mar 24, 2026